武汉艾必赛生物有限公司推荐Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Besnotamig, RUO) ,精品抗体

链接：https://www.abinscience.cn/product/34/56270.html

名称：Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Besnotamig, RUO)

货号：HY257086

种属反应性：Human

应用：ELISA, FACS, Functional assay

宿主：Human

同种型：immunoglobulin (H-gamma4_L-kappa)_(VH-G4(CH1)(_L kappa)-1mer-VH-TRBC2-G4(9h-CH2-CH3)_V-kappa-TRAC)

克隆类型：Monoclonal

靶标：B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1, CD3E, CD3e, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, T3E

内毒素水平：< 10 EU/mg

纯度：>95% as determined by SDS-PAGE.

纯化方式：Protein A/G purified from cell culture supernatant.

Accession号：P11836 & P07766

状态：Liquid

用途范围：仅用于科研

储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

 

产品介绍：Anti-Human CD20 & CD3 epsilon Bispecific Reference Antibody (Besnotamig, RUO)｜HY257086 是艾必赛生物（abinScience）推出的人源化双特异性 T 细胞接合参照抗体（人 IgG），可同时靶向 B 细胞表面的 CD20 与 T 细胞受体复合物中的 CD3ε，用作 CD20×CD3 双抗药物开发、PK/ADA 方法建立及 T 细胞接合功能 assay 的阳性/药物参照质控工具。该抗体在哺乳动物细胞中表达，经 Protein A/G 纯化，纯度 >95%（SDS-PAGE），以液体形式保存在 0.01M PBS, pH 7.4 中；短期 4°C（1–2 周），长期建议 -20°C（≤12 个月）/ -80°C 避反复冻融使用，应用于 ELISA、FACS、Functional assay 等。（RUO，仅限科研/非临床用途）

CD20×CD3 双特异性抗体是当下 B 细胞恶性肿瘤治疗最具突破性的方向之一：抗体一端结合 B 细胞上的 CD20（MS4A1），另一端结合 T 细胞 CD3ε，从而将 T 细胞与肿瘤细胞物理桥联，触发 TCR 下游信号、T 细胞活化与增殖，并释放穿孔素/颗粒酶等效应分子杀伤 CD20+ 恶性 B 细胞。Besnotamig 所属的 CD20/CD3 双抗赛道已有 Mosunetuzumab、Glofitamab、Epcoritamab、Odronextamab 等多款药物获批用于复发/难治性 B 细胞淋巴瘤，验证了该靶点对滤泡性淋巴瘤、弥漫大 B 细胞淋巴瘤（DLBCL）等适应症的高效性。

 

 

 

产品购买联系方式：027-87433958/17302791434

邮箱：info@abinscience.com

参考文献：

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. PMID: 25972002

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. PMID: 29716920

The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. PMID: 32482755

Derisking CD20-therapies for long-term use. PMID: 34902761

Targeting CD20: teaching an old dog new tricks. PMID: 31808844

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. PMID: 38048694

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. PMID: 23211638

CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. PMID: 32314054

CD20(+) T cells: an emerging T cell subset in human pathology. PMID: 35951029

CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion. PMID: 40724904

CD3(+)CD20(+) T cells and their roles in human diseases. PMID: 30639700

CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies. PMID: 28067179

Targeting CD20 in multiple sclerosis - review of current treatment strategies. PMID: 36999373

CD20 role in pathophysiology of Hodgkin's disease. PMID: 29239464

Complement system in Anti-CD20 mAb therapy for cancer: A mini-review. PMID: 37357623

Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy. PMID: 36603540

Anti-CD20 antibody treatment of non-Hodgkin lymphomas. PMID: 27531574

CD20-mediated apoptosis: signalling through lipid rafts. PMID: 12383196

Current Knowledge about CD3(+)CD20(+) T Cells in Patients with Multiple Sclerosis. PMID: 39201672

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. PMID: 38475814

CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. PMID: 27075017

The applications of anti-CD20 antibodies to treat various B cells disorders. PMID: 30551501

CD20 and Outcome of Childhood Precursor B-cell Acute Lymphoblastic Leukemia: A Meta-analysis. PMID: 25222059

Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better? PMID: 30483893

Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease. PMID: 35367516

Anti-CD20 monoclonal antibody therapy in multiple myeloma. PMID: 18318769

CD20: a gene in search of a function. PMID: 11225995

Proinflammatory CD20(+) T cells contribute to CNS-directed autoimmunity. PMID: 35353539

CD20-targeted therapy: the next generation of antibodies. PMID: 20350667

Engineering CD20 CARs with a Twist. PMID: 36633575

CD20: a target antigen for immunotherapy of autoimmune diseases. PMID: 16214090

Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. PMID: 31059839

Canine CD20 gene. PMID: 16061290

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. PMID: 23256681

Anti-CD20 monoclonal antibodies: historical and future perspectives. PMID: 19773256

Characterization of CD3+/CD20+ canine large-cell lymphoma. PMID: 37837199

The biology of CD20 and its potential as a target for mAb therapy. PMID: 15564720

The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. PMID: 30084674

Anti-CD20 therapeutic options in immune-mediated thrombotic thrombocytopenic purpura. PMID: 35472189

CD20 antigen expression by lymphoma cells in lung allograft recipients is associated with higher remission rate and superior survival: a study on heart and lung transplant recipients. PMID: 24434379

 

 

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com

武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。